Golumbeski George

SEC source: 0001628280-26-041268 · wk-form4_1780691316.xml · derivative · entry 2

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,250

Underlying: Common Stock · 53,250 shares

Expires 2036-06-03

F2 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001628280-26-041268 · wk-form4_1780691316.xml · nonDerivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,500

F1 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001193125-26-254126 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2036-05-29

F1 · derivative.exercise_date: This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001193125-25-308770 · ownership.xml · derivative · entry 2

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 15,334 shares

Expires 2034-07-29

F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

SEC source: 0001193125-25-308770 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 8,637 shares

Expires 2035-06-10

F2 · price: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").

F2 · derivative.exercise_date: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.

SEC source: 0001586660-25-000003 · wk-form4_1762811342.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-11-06

F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control.

SEC source: 0000950170-25-100666 · ownership.xml · derivative · entry 3

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,500 shares

Expires 2035-06-10

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

SEC source: 0000950170-25-100666 · ownership.xml · derivative · entry 2

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,593 shares

Expires 2035-01-03

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

SEC source: 0000950170-25-100666 · ownership.xml · nonDerivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.

F2 · kind: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.

F2 · price: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.

SEC source: 0000950170-25-096275 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,150

Underlying: Common Stock · 33,150 shares

Expires 2035-07-14

F1 · derivative.exercise_date: This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0000950170-25-085818 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,637

Underlying: Ordinary Shares · 8,637 shares

Expires 2035-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2025. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer.

SEC source: 0001562180-25-004793 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2035-06-11

F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

SEC source: 0001562180-25-000164 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,593

Underlying: Common Stock · 13,593 shares

Expires 2035-01-03

F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2025 on the issuer's board or its committees, as permitted under the issuer's non-employee director compensation program. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. The option will vest in full on December 31, 2025, subject to the reporting person's continued service through such date.

SEC source: 0000950170-24-088534 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,334

Underlying: Ordinary Shares · 15,334 shares

Expires 2034-07-29

F1 · derivative.exercise_date: This option was granted on July 30, 2024. This option shall vest in 12 equal quarterly installments over three years from the date of grant.

SEC source: 0000950170-24-076393 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,700

Underlying: Common Stock · 27,700 shares

Expires 2034-06-21

F1 · derivative.exercise_date: This option represents the right to purchase a total of 27,700 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001562180-24-004952 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2034-06-09

F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

SEC source: 0001562180-24-000224 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,495

Underlying: Common Stock · 3,495 shares

Expires 2034-01-03

F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date.

SEC source: 0001562180-23-005260 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

SEC source: 0000950170-23-025375 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,258

Underlying: Common Stock · 40,258 shares

Expires 2023-05-26

F1 · derivative.exercise_date: This option represents the right to purchase a total of 40,258 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001562180-23-000235 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,108

Underlying: Common Stock · 2,108 shares

Expires 2033-01-04

F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2023 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2023, subject to the reporting person's continued service through such date.

SEC source: 0001562180-22-005205 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,947

Underlying: Common Stock · 9,947 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

SEC source: 0000899243-22-021918 · doc4.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,258

Underlying: Common Stock · 40,258 shares

Expires 2032-06-08

F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,258 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001562180-22-003898 · primarydocument.xml · nonDerivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $31.33 USD to $31.50 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000899243-22-015764 · doc4.xml · nonDerivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,613

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.505 to $3.78. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000899243-22-015609 · doc4.xml · nonDerivative · entry 2

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,283

SEC source: 0000899243-22-015609 · doc4.xml · nonDerivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,049

F1 · price: This transaction was executed in multiple trades at prices ranging from $3.62 to $3.80. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001562180-22-000233 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,638

Underlying: Common Stock · 1,638 shares

Expires 2032-01-04

F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2022 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2022, subject to the reporting person's continued service through such date.

SEC source: 0000899243-21-025422 · doc4.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,434

Underlying: Common Stock · 3,434 shares

Expires 2031-06-19

F1 · derivative.exercise_date: This option represents a right to purchase a total of 3,434 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001562180-21-004209 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-10

F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

SEC source: 0001562180-21-000192 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 832

Underlying: Common Stock · 832 shares

Expires 2031-01-05

F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for his service during 2021 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2021, subject to the reporting person's continued service through such date.

SEC source: 0000899243-20-035206 · doc4.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,286

Underlying: Common Stock · 1,286 shares

Expires 2030-12-22

F1 · derivative.exercise_date: This option represents a right to purchase a total of 1,286 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001493152-20-012802 · ownership.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,000

Underlying: Common Stock · 81,000 shares

Expires 2030-07-06

F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.

SEC source: 0001562180-20-004429 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-09

F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

SEC source: 0001177648-20-000014 · edgar.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-02-26

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 26, 2020), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2021 annual meeting of stockholders.

SEC source: 0001562180-20-000275 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 976

Underlying: Common Stock · 976 shares

Expires 2030-01-03

F1 · derivative.exercise_date: The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for his service during 2020 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2020, subject to the reporting person's continued service through such date.

SEC source: 0001562180-19-003393 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2029-06-05

F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

SEC source: 0001177648-19-000028 · edgar.xml · derivative · entry 3

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,280 shares

Expires 2024-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-19-000028 · edgar.xml · nonDerivative · entry 2

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2018.

SEC source: 0001177648-19-000028 · edgar.xml · nonDerivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,280

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-19-000021 · edgar.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2029-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2019), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2020 annual meeting of stockholders.

SEC source: 0001177648-19-000005 · edgar.xml · derivative · entry 8

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-19-000005 · edgar.xml · derivative · entry 7

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,728 shares

Expires 2026-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-19-000005 · edgar.xml · nonDerivative · entry 5

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2018.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.0672 to $90.0716, inclusive.

SEC source: 0001177648-19-000005 · edgar.xml · nonDerivative · entry 4

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,228

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-19-000005 · edgar.xml · nonDerivative · entry 3

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-19-000005 · edgar.xml · derivative · entry 6

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,728

Underlying: Common Stock · 2,272 shares

Expires 2026-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-19-000005 · edgar.xml · nonDerivative · entry 2

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2018.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.0307 to $90.0323, inclusive.

SEC source: 0001177648-19-000005 · edgar.xml · nonDerivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-19-000489 · primarydocument.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2029-01-22

F1 · derivative.exercise_date: All of the shares subject to the option vest in equal monthly installments during the 36 months following January 22, 2019 (the "Grant Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Grant Date, subject to the reporting person's continued service as a director of the issuer through such date.

SEC source: 0001177648-18-000013 · edgar.xml · derivative · entry 1

Golumbeski George · CIK 0001586660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2028-02-28

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders.